rss
Ann Rheum Dis 2000;59:487-489 doi:10.1136/ard.59.6.487
  • Concise report

An audit of cyclosporin for systemic lupus erythematosus and related overlap syndromes: limitations of its use

  1. S J Morton,
  2. R J Powell
  1. Clinical Immunology Unit, University Hospital, Queens Medical Centre, Nottingham NG27 2UH, UK
  1. Dr Powell Email: sheena007{at}hotmail.com
  • Accepted 28 January 2000

Abstract

OBJECTIVE To establish the usefulness of cyclosporin for systemic lupus erythematosus (SLE) in a routine clinical setting.

METHODS Patients who had received cyclosporin for SLE, mixed connective tissue disease, and other overlap syndromes were identified. Data relating to treatment with cyclosporin, including dosage, concurrent steroid use, response to treatment, side effects, and reasons for withdrawal, were extracted from medical notes.

RESULTS A total of 43 patients had been treated with cyclosporin between 1995 and 1998. Cyclosporin, average dose 4 mg/kg/d, was started in patients whose disease was active despite previous use of alternative second line agents. On every occasion when cyclosporin was used for thrombocytopenia the response was good, but when arthritis was the indication, the response was good in 14/26. The success rates for symptoms of arthralgia, myalgia, and fatigue were lower. Side effects occurred in 28/43 (65%) cases, and on 39/47 (83%) occasions cyclosporin was withdrawn owing to either side effects or failure to control disease activity, after a median duration of treatment of only four months.

CONCLUSIONS The response to cyclosporin is mixed and usually short lived.

Footnotes

    Register for free content

    The full back archive is now available for all BMJ Journals. Institutional subscribers may access the entire archive as part of their subscription. Personal subscribers will also have access to all content when logged in. Non-subscribers who register have free access to all articles published before 2006 right back to volume 1 issue 1. Register here to access the free archive of all BMJ Journals.

    Don't forget to sign up for content alerts so you keep up to date with all the articles as they are published.